Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60074 |
Name | ductal carcinoma in situ |
Definition | A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has_material_basis_in abnormally proliferating cells, derives_from epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation pre-malignant neoplasm in situ carcinoma breast carcinoma in situ ductal carcinoma in situ |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01097278 | Phase 0 | Cholecalciferol | S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer | Completed | USA | 0 |
NCT02540330 | Phase II | Fulvestrant | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant (007) | Terminated | USA | 0 |
NCT02636582 | Phase II | Sargramostim Nelipepimut-S Plus GM-CSF | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | Completed | USA | 0 |
NCT02694809 | Phase II | Conjugated estrogens-bazedoxifene | Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery | Completed | USA | 0 |
NCT02872025 | Phase I | Pembrolizumab | Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS) | Active, not recruiting | USA | 0 |
NCT02928978 | Phase II | Ruxolitinib | Ruxolitinib for Premalignant Breast Disease | Active, not recruiting | USA | 0 |
NCT02993159 | Phase II | Afimoxifene Tamoxifen | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | Completed | USA | 0 |
NCT03535506 | Phase II | Palbociclib | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery (WI223281) | Terminated | USA | 0 |
NCT04666961 | Phase II | Anastrozole + Tamoxifen | Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ (HORNEO01) | Recruiting | FRA | 0 |